GoodRx for Healthcare Professionals9 Medications That Cause Joint and Muscle Pain

This article provides patient-oriented information on medications associated with joint and muscle pain, which is critical for clinical counseling and medication adherence. The content serves as a valuable education tool for discussing medication side effects with patients who may experience musculoskeletal complaints from common prescriptions.

⚕️Key Clinical Considerations⚕️

• Nine medication classes associated with joint/muscle pain include statins, fluoroquinolones, fibrates, bisphosphonates, teriparatide, aromatase inhibitors, oral steroids, isotretinoin, and pregabalin, each with distinct manifestation patterns and risk profiles.
• Fluoroquinolones carry FDA warnings for tendon damage risk, with levofloxacin showing higher tendon rupture rates and ciprofloxacin more associated with tendonitis, particularly in patients over 60, those on corticosteroids, or with transplant history.
• Aromatase inhibitors cause joint pain in up to 50% of patients within the first year of treatment, representing the primary reason for treatment discontinuation in breast cancer therapy.
• Statin-induced myopathy may be less common than previously believed, with a 2022 study suggesting most attributed muscle pain may have other causes, though simvastatin appears more likely to cause muscle effects than pravastatin.
• Management approaches include dose reduction (e.g., with statins), medication switches, non-pharmacological interventions (compresses, exercise), and appropriate OTC analgesics after prescriber consultation.

🎯 Clinical Practice Impact 🎯

• Patient Communication: When patients report joint or muscle pain, clinicians should systematically evaluate the medication list, considering onset timing relative to medication initiation. Discuss the risk-benefit profile of continuing therapy versus alternative treatments based on symptom severity and medical necessity.
• Risk Management: Monitor for serious complications like rhabdomyolysis with statins and fibrates, particularly in high-risk patients (elderly, diabetics, renal impairment). The fibrate-statin combination, especially gemfibrozil-simvastatin, requires particular caution due to increased myopathy risk.
• Practice Integration: Consider patient-specific risk factors when prescribing medications with myalgia potential: women, older adults (>65), diabetics, and those with preexisting musculoskeletal conditions represent higher-risk populations for medication-induced joint and muscle complaints.
• Action Items: Develop a stepwise approach to managing medication-induced musculoskeletal complaints: 1) assess severity and medication necessity, 2) consider dose adjustment when appropriate, 3) evaluate alternative medications with lower myopathy risk, and 4) implement supportive non-pharmacological strategies.

More on Side Effects